Compass Pathways Successfully Achieves Primary Endpoint In First Phase 3 Trial

Reuters
23 Jun
June 23 (Reuters) - Compass Pathways PLC ::
*COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION
*COMPASS PATHWAYS PLC - COMP360 SHOWS SIGNIFICANT REDUCTION IN SYMPTOM SEVERITY IN PHASE 3 TRIAL
*COMPASS PATHWAYS PLC - DSMB FINDS NO UNEXPECTED SAFETY ISSUES WITH COMP360
*COMPASS PATHWAYS PLC - COMP006 TRIAL 26-WEEK DATA EXPECTED IN SECOND HALF OF 2026

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 23-JUN-202510:30:00.18 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10